The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
Aveo gets Fotivda over the line in the US, but the market celebration looks misplaced.
Merck & Co/Eisai’s Clear study results look better than Bristol/Exelixis’s Checkmate-9ER, but the big loser could be Pfizer.
The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.
The company welcomes in 2021 with the failure of a pivotal study of its pipeline lead, telaglenastat.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.